LifeMD (NASDAQ:LFMD) Stock Price Target Cut by HC Wainwright

LifeMD (NASDAQ:LFMD – Get Free Report) had its target price decreased by HC Wainwright from $9.00 to $6.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright‘s price target suggests a potential upside of 276.18% from the company’s previous close.

A number of other research firms have also recently issued reports on LFMD. Weiss Ratings restated a “sell (d)” rating on shares of LifeMD in a report on Monday, November 2nd. BTIG Research lowered their price objective on shares of LifeMD from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Zacks Research upgraded shares of LifeMD from a “strong sell” rating to a “hold” rating in a research report on Monday, August 17th. Mizuho cut their target price on shares of LifeMD from $7.00 to $6.00 and set an “outperform” rating on the stock in a research note on Friday, November 13th. Finally, KeyCorp set a $5.00 price target on shares of LifeMD and gave the stock an “overweight” rating in a report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $6.71.

Read Our Latest Research Report on LifeMD

LifeMD Price Performance

Shares of NASDAQ:LFMD opened at $1.59 on Wednesday. The company has a market capitalization of $77.09 million, a price-to-earnings ratio of -26.58 and a beta of 2.19. The business’s 50-day moving average is $2.50 and its 200-day moving average is $3.54. LifeMD has a 1 year low of $1.53 and a 1 year high of $5.38.

LifeMD (NASDAQ:LFMD – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.03. The business had revenue of $44.63 million during the quarter, compared to analysts’ expectations of $48.84 million. LifeMD had a negative return on equity of 188.63% and a negative net margin of 0.25%. Analysts anticipate that LifeMD will post -0.48 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of LFMD. Goldman Sachs Group Inc. raised its stake in shares of LifeMD by 133.4% during the 3rd quarter. Goldman Sachs Group Inc. now owns 232,501 shares of the company’s stock worth $674,000 after purchasing an additional 132,883 shares during the period. Marshall Wace LLP boosted its holdings in shares of LifeMD by 45.1% in the 3rd quarter. Marshall Wace LLP now owns 809,138 shares of the company’s stock worth $2,347,000 after buying an additional 251,664 shares during the last quarter. Empowered Funds LLC purchased a new position in shares of LifeMD in the 3rd quarter worth about $160,000. Cibc World Market Inc. grew its position in LifeMD by 112.3% during the third quarter. Cibc World Market Inc. now owns 63,700 shares of the company’s stock valued at $185,000 after buying an additional 33,700 shares during the period. Finally, Chapin Davis Inc. bought a new position in LifeMD during the third quarter valued at about $29,000. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

(Get Free Report)

LifeMD, Inc. is a virtual healthcare company that connects patients with medical providers through its telehealth platform. Its services include virtual primary care and specialty care, with offerings in areas such as men’s health and weight management. The company operates the LifeMD and Rex MD brands and supports care through online consultations, treatment plans and, when prescribed, medication. Service availability and treatment options may vary by state and individual patient needs. LifeMD serves patients in the United States.

Recommended Stories

Analyst Recommendations for LifeMD (NASDAQ:LFMD)

Receive News & Ratings for LifeMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeMD and related companies with MarketBeat.com's FREE daily email newsletter.